247569-56-8

Basic information

• Product Name: 2-Fluoro-5-Methanesulfonylbenzoic acid
• Synonyms: 2-Fluoro-5-Methanesulfonylbenzoic acid;2-Fluoro-5-(Methylsulfonyl)benzoic acid;2-Fluro-5-methanesulfonyl benzoic acid;2-fluoro-6-methanesulfonyl-benzoic acid
• CAS NO: 247569-56-8
• Molecular Formula: C₈H₇FO₄S
• Molecular Weight: 218.2021832
• EINECS: -0
• Mol File: 247569-56-8.mol

Chemical Properties

• Boiling Point: 438.3±45.0 °C(Predicted)
• Appearance: /
• Density: 1.474±0.06 g/cm3(Predicted)
• Vapor Pressure: 0.001Pa at 25℃
• PKA: 2.67±0.10(Predicted)
• CAS DataBase Reference: 2-Fluoro-5-Methanesulfonylbenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Fluoro-5-Methanesulfonylbenzoic acid(247569-56-8)
• EPA Substance Registry System: 2-Fluoro-5-Methanesulfonylbenzoic acid(247569-56-8)

Safety Data

• Hazardous Substances Data: 247569-56-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Fluoro-5-Methanesulfonylbenzoic acid is used as a potent 5-HT1A receptor agonist for the potential future treatment of depression. Its ability to selectively target and activate the 5-HT1A receptors plays a crucial role in modulating the serotonin levels in the brain, which is essential for addressing depressive symptoms and improving mood regulation.

Upstream product

• 865663-98-5 2-fluoro-5-methanesulfonylbenzoic acid methyl ester 
• 109-89-7 diethylamine 
• 37098-75-2 2-fluoro-5-chlorosulfonylbenzoic acid 
• 79-11-8 chloroacetic acid 
• 57318-98-6 2-fluoro-5-(methylthio)benzoic acid 
• 445-29-4 o-fluoro-benzoic acid 
• 1229627-84-2 2-fluoro-5-sulfinobenzoic acid 

Downstream Products

• 845616-02-6 2-isopropoxy-5-methanesulfonyl-benzoic acid 
• 459833-28-4 2-ethoxy-5-methanesulfonyl-benzoic acid 
• 845616-82-2 5-methane-sulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-benzoic acid 
• 845616-83-3 rac-5-methanesulfonyl-2-(2,2,2-trifluoro-1-methylethoxy)benzoic acid 

Relevant articles and documents

Bitopertin synthetic method and intermediate

The present invention discloses a new synthesis method and intermediates of Bitopertin. According to the Bitopertin synthesis method, 5-methylsulfonyl-2-[(1S)-2,2,2-trifluoro-1-methylethoxy]benzoic acid is adopted as a raw material, and continuous multi-step operations such as chlorination, acylation, deprotection, condensation and re-crystallization are subjected to performed to obtain the Bitopertin, wherein the intermediates in each step do not require further purification, and the total yield can achieve more than or equal to 80%.

2-Substituted-phenyl-oxy-5-methylsulfonyl piperazine acidamide analogue and preparation method and application thereof

The invention discloses 2-substituted-phenyl-oxy-5-methylsulfonyl piperazine acidamide analogue and a preparation method and application thereof, and particularly, relates to 2-substituted-phenyl-oxy-5-methylsulfonyl piperazine acidamide analogue with a formula (I) compound and a preparation method and application thereof, wherein substitutions in the formula (I) compound are defined as in the description. This serial compound can inhibit the activity of glycine transport protein-1 (GlyT1), is useful in treating related diseases in central nerve and psychological fields, for example, schizophrenia (including positive symptoms, negative symptoms and cognitive symptoms), senile dementia, Parkinson's disease and other related psychological diseases, is widely applicable to the drugs for preventing and treating central nerve and psychological diseases, and is expected to be developed into new-generation GlyT1 inhibitors.

Selective GlyT1 inhibitors: Discovery of [4-(3-fluoro-5- trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2, 2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia

The GlyT1 transporter has emerged as a key novel target for the treatment of schizophrenia. Herein, we report on the optimization of the 2-alkoxy-5-methylsulfonebenzoylpiperazine class of GlyT1 inhibitors to improve hERG channel selectivity and brain penetration. This effort culminated in the discovery of compound 10a (RG1678), the first potent and selective GlyT1 inhibitor to have a beneficial effect in schizophrenic patients in a phase II clinical trial.

SYNTHESIS OF GLYT-1 INHIBITORS

The present invention relates to a process for preparation of a compound of formula I wherein Het, R1, R2, R3, and n are as defined herein and pharmaceutically acceptable acid addition salts thereof, which comprises reacting a compound of formula 21 with a compound of formula 8 to obtain a compound of formula 11 and coupling the compound of formula 11 in the presence of a coupling reagent or the corresponding acid halogenide with a compound of formula 15 to obtain a compound of formula I.

Substituted phenyl methanones

The present invention relates to compounds of general formula IA or IB wherein X1 and X2 are each independently N or C—R″ and R1, R2,R3, R4, R5, and R6 are as defined

Sulfanyl substituted phenyl methanones

The present invention relates to compounds of formula I wherein R1, R2, R3, X, X1, and n are as defined in the specification and pharmaceutically acceptable acid addition salts thereof. These compounds are good inhibitors of the glycine transporter 1 (GlyT-1) for the treatment CNS disorders, such as schizophrenia, cognitive impairment, and Alzheimer's disease.

[4-(HETEROARYL) PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS

The present invention relates to compounds of the general formula (I) wherein R1 is-OR1’,-SR1’ or is a heterocycloalkyl group; R1’ is lower alkyl, lower alkyl substituted by halogen or is -(CH2)n

Substituted phenyl methanone derivatives

The present invention relates to compounds of formula I wherein R1, R2, R3, n, and m, are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. These compounds are good inhibitors

Heterocyclic-substituted phenyl methanones

The present invention relates to compounds of formula I wherein R1, R2, and are defined in the specification and to pharmaceutically acceptable acid addition salts thereof.